Melanotan 2 vs PT-141 (Bremelanotide): What the Research Shows

Research Use Only. The information below summarizes preclinical and pharmacological literature for laboratory and educational reference. It is not for human or veterinary use, and nothing here describes or encourages administration, dosing, or any use in people or animals.

Melanotan 2 and PT-141 (bremelanotide) are two of the most frequently referenced melanocortin research peptides, and they are closely related at the molecular level. Because they share a common lineage, they are often confused. This overview looks at how the two compounds differ in structure and receptor behavior, and how each has been characterized in the published research literature. For the broader context, see our melanocortin research peptides overview.

What are Melanotan 2 and PT-141

Both compounds are synthetic cyclic peptide analogs of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural ligand at the melanocortin family of receptors. Melanotan 2 was developed first, as a broadly active melanocortin receptor agonist. PT-141, also called bremelanotide, is the primary active metabolite of Melanotan 2, formed when the C-terminal amide of Melanotan 2 is cleaved to a free acid.

The practical consequence of that small structural change is a shift in receptor preference. Melanotan 2 is a non-selective agonist that engages several melanocortin receptor subtypes, including MC1R (linked in the literature to pigmentation pathways) and MC4R (linked to central appetite and sexual-behavior circuits). PT-141 retains strong activity at MC3R and MC4R but has a comparatively reduced pigmentation-associated profile. In short, PT-141 can be thought of as a more MC4R-weighted derivative of the broader Melanotan 2 scaffold. You can read each compound on its own in our Melanotan 2 research summary and our PT-141 research summary.

Where they sit in the research literature

The melanocortin system is a well-studied signaling network, and both peptides appear across a range of preclinical and pharmacological investigations. Reported research areas described in third-party literature include the following.

Reported preclinical and pharmacological areas

• Characterization of melanocortin receptor binding and subtype selectivity in receptor and cell-based assays.
• Studies of MC1R signaling and melanogenesis pathways in cultured pigment cells, more associated with Melanotan 2.
• Investigations of MC3R and MC4R signaling in central nervous system circuits in animal models, relevant to both compounds.
• Systematic reviews examining MC4R as a pharmacological target in energy-balance and appetite research.
• Pharmacological profiling of the cardiovascular signals associated with MC4R agonism, including transient blood pressure and heart-rate effects measured in controlled studies.
• Exploratory work repositioning melanocortin agonists in unrelated cell-biology contexts, such as receptor-mediated effects in tumor cell lines.

These descriptions reflect what independent researchers have reported. They are not claims about outcomes in humans and do not describe any intended effect of the material sold by Pure Chems.

Chemistry and notes at a glance

• Compound class: both are cyclic heptapeptide analogs of alpha-MSH.
• Relationship: PT-141 (bremelanotide) is the active metabolite of Melanotan 2.
• Melanotan 2 receptor profile: broad, non-selective melanocortin agonist (MC1R, MC3R, MC4R, MC5R).
• PT-141 receptor profile: weighted toward MC3R and MC4R, reduced pigmentation-associated activity.
• Physical form: typically supplied as a lyophilized (freeze-dried) white powder for laboratory reconstitution.
• Handling: both are peptides and share the same storage and stability considerations as other research peptides.

Why the "research use only" label matters

In the EU, research peptides such as Melanotan 2 and PT-141 are handled as laboratory chemicals, not as medicines. That classification only holds while the material is described and supplied strictly for in vitro and laboratory research, with no therapeutic or human-use framing. As soon as a product is presented for human use, it can fall under EU medicines legislation and the associated approval requirements.

There is also a documented safety signal worth noting honestly. Melanocortin-4 receptor agonism has been associated in the pharmacological literature with small, transient increases in blood pressure and changes in heart rate. In a controlled pharmacology study of bremelanotide, ambulatory monitoring detected modest short-lived blood pressure increases relative to placebo. This is one reason melanocortin agonists are studied carefully under controlled conditions and why the compounds are supplied for research contexts only.

On regulatory status the two compounds diverge. Bremelanotide (the PT-141 molecule) has been developed and, in some jurisdictions, approved as a pharmaceutical product under a specific brand and indication. Melanotan 2 has not been approved as a medicine in the EU or elsewhere and exists on the market only as a research chemical. Neither status changes the research-use-only framing under which Pure Chems supplies these materials.

Handling and storage for researchers

As lyophilized peptides, Melanotan 2 and PT-141 are generally most stable when stored cold, dry, and protected from light. Common laboratory practice keeps sealed lyophilized vials in a freezer for long-term storage and refrigerated once reconstituted, minimizing repeated freeze-thaw cycles. Reconstitution is performed with an appropriate research solvent depending on the experiment. For a fuller treatment of solvent choice and stability, see our guides on peptide storage and stability and on reconstitution solvents.

Frequently asked questions

Are Melanotan 2 and PT-141 the same thing?

No, but they are closely related. PT-141 (bremelanotide) is the active metabolite of Melanotan 2. The two share a common peptide scaffold, but PT-141 has a shifted receptor profile that is more weighted toward MC3R and MC4R and comparatively less toward the pigmentation-associated MC1R pathway.

Which one is more selective?

In the published pharmacology, PT-141 is generally described as the more MC4R-weighted of the two, while Melanotan 2 is characterized as a broadly non-selective melanocortin agonist. Selectivity is a research property measured in receptor assays, not a statement about any use.

Is either compound approved by regulators?

Bremelanotide (PT-141) has been developed as a pharmaceutical and approved in some jurisdictions for a specific medical indication. Melanotan 2 has not been approved as a medicine. Regardless of approval status, both are supplied by Pure Chems strictly as research chemicals for laboratory use only.

Is it legal to buy Melanotan 2 or PT-141 for research in the EU?

Within the EU, these peptides are generally available as research chemicals when supplied and documented for laboratory research use only, without any human-use or therapeutic claims. Requirements can vary by member state, so researchers should confirm the rules that apply in their own country and institution before purchasing.

What form do they ship in?

Both are typically supplied as a lyophilized white powder in a sealed vial, which researchers reconstitute in the laboratory with a suitable solvent.

Key takeaways

• Melanotan 2 and PT-141 are related cyclic alpha-MSH analogs; PT-141 (bremelanotide) is the active metabolite of Melanotan 2.
• Melanotan 2 is a broad, non-selective melanocortin agonist, while PT-141 is more weighted toward MC3R and MC4R.
• The published literature covers receptor selectivity, central melanocortin signaling, MC4R as a research target, and a documented transient cardiovascular signal with MC4R agonism.
• Bremelanotide has pharmaceutical approval in some jurisdictions; Melanotan 2 does not. Both are supplied for research use only.
• Both are lyophilized peptides that follow standard cold, dry, light-protected storage practice.

References

References sourced via PubMed.

1. Fani L, Bak S, Delhanty P, van Rossum EFC, van den Akker ELT. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. International Journal of Obesity. 2014. https://doi.org/10.1038/ijo.2013.80 | https://pubmed.ncbi.nlm.nih.gov/23774329/
2. White WB, Myers MG, Jordan R, Lucas J. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. Journal of Hypertension. 2017. https://doi.org/10.1097/HJH.0000000000001221 | https://pubmed.ncbi.nlm.nih.gov/27977473/

Disclaimer: All products and information are for research use only (RUO) and are not for human or veterinary use. Nothing on this page is a therapeutic or medical claim, and none of it describes or encourages use in people or animals. Melanotan 2 is available in our catalog as a research chemical; explore related materials in our Melanotan 2 research listing.